Carboplatin dosing in infants with retinoblastoma: A case for therapeutic drug monitoring

Journal of Clinical Oncology

Volumn 30, Issue 27, 2012, Pages 3424-

  Veal, Gareth J ^a   Boddy, Alan V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN;

AREA UNDER THE CURVE; BODY SURFACE; BODY WEIGHT; DRUG CLEARANCE; DRUG DISPOSITION; DRUG MONITORING; DRUG RESPONSE; GLOMERULUS FILTRATION RATE; HEARING LOSS; HUMAN; KIDNEY FUNCTION; LETTER; OTOTOXICITY; PEDIATRICIAN; PRIORITY JOURNAL; RETINOBLASTOMA; RISK FACTOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HEARING; HEARING LOSS; HUMANS; MALE; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 84866760051     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.5677     Document Type: Letter

References (6)

1. Leahey A: A cautionary tale: Dosing chemotherapy in infants with retinoblastoma. J Clin Oncol 30:1023-1024, 2012
2. Qaddoumi I, Bass JK, Wu J, et al: Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30:1034-1041, 2012
3. Thomas H, Boddy AV, English MW, et al: Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group trial. J Clin Oncol 18:3614-3621, 2000
4. Veal GJ, Cole M, Errington J, et al: Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemother Pharmacol 65: 1057-1066, 2010
5. Veal GJ, Errington J, Tilby MJ, et al: Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. Br J Cancer 96:725-731, 2007 (Pubitemid 46376616)
6. Picton SV, Keeble J, Holden V, et al: Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. Cancer Chemother Pharmacol 63:749-752, 2009